The New Frontier of Immuno-Oncology

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.

About Pionyr Immunotherapeutics

The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

Learn More

Our Science

Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.

Learn More

Pionyr Pipeline

Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.

Program (Target)
PY314 (TREM2) / Depletion
PY159 (TREM1) / Repolarization
PI-114 / Immune Actuation
PI-115 / Antigen Presentation
TME Targeting

Become a Pionyr

Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.

Learn More

Upcoming Events

March 4, 2021
Academic Drug Discovery Consortium
Webinar on Bioentrepreneurship
April 10-15, 2021 and May 17-21, 2021
AACR Annual Meeting, Virtual
Pionyr Poster Presentation
July 19-21, 2021
PEGS Summer Symposium, Virtual
Pionyr Presentation

Recent News

November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

More News

Contact Us

Pionyr Immunotherapeutics Inc.
2 Tower Pl, Suite 800
South San Francisco, CA 94080
(650) 825-6140